Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

ESMO-Congress-2020-1000x250

ESMO Virtual Congress 2020, the world's premier virtual congress in medical oncology!

​The congress will attract an international community of experts, across disciplines and all focused on finding the most effective cancer treatment solutions available today.

This is the ultimate goal of the ESMO Virtual Congress 2020 and we count on our Industry Partners active in oncology to help us again further our science and improve the lives of patients through continued education.

Fast Facts: ESMO Congress 2019

  • 29’622 participants, 137 countries
  • 8’426 sqm exhibition space, 188 exhibitors
  • 588 invited speakers
  • 212 sessions ESMO, 15 sessions EONS
  • 3’904 submitted abstracts

How can I participate in 2020?

At ESMO we are committed to providing our industry partners with a variety of solutions to facilitate your presence at our congress.

Contact the  ESMO Events Sponsorship Team for more details and we look forward to hearing from you!

Who has already signed up?

We gratefully acknowledge the valuable contribution of the following organisations in the ESMO 2020 Congress through their presence in the virtual exhibition, organisation of sponsored sessions, or via sponsorship activities (as of July 2020):

  • Advanced Accelerator Applications, a Novartis company
  • Agendia
  • Alkermes, Inc.
  • Amgen (Europe) GmbH
  • Amoy Diagnostics Co., Ltd.
  • Aptitude Health
  • ArcherDX
  • Astellas Pharma Europe Ltd.
  • AstraZeneca
  • Bayer
  • Beacon Medicare Limited
  • BeiGene
  • Biocartis
  • Biognosys
  • BMJ
  • BMS Pfizer Alliance
  • Boehringer Ingelheim International GmbH
  • Bristol-Myers Squibb
  • Calithera Biosciences
  • Cancers MDPI
  • Caris Life Sciences
  • Catalysis S.L.
  • CeGaT
  • Celltrion Healthcare Co., Ltd.
  • COR2ED
  • Daiichi Sankyo
  • Debiopharm
  • Deciphera Pharmaceuticals, LLC
  • Eisai Europe Ltd.
  • Eli Lilly and Company
  • Elsevier
  • Erytech Pharma
  • EUSA Pharma Limited
  • Exact Sciences
  • Exelixis
  • F.Hoffmann-La Roche LTD.
  • Ferring International Center SA
  • Genmab
  • GSK
  • Guardant Health, Inc.
  • HalioDx
  • Illumina
  • Immunomedics
  • Incyte Biosciences International Sarl
  • Ipsen
  • ITM Isotopen Technologien Muenchen AG
  • JAMA Network
  • Janssen Pharmaceutica NV
  • Kaiku Health
  • Karger Publishers
  • Kite, a Gilead Company
  • Kyowa Kirin International
  • LeCancer.fr
  • Med Learning Group
  • medac GmbH
  • MEDIAN Technologies
  • Medscape Oncology
  • Menarini Silicon Biosystems
  • Merck KGaA
  • Molecular Health
  • MSD
  • Mylan GmbH
  • Myriad Genetics
  • National Comprehensive Cancer Network (NCCN)
  • NEJM Group
  • NeoGenomics
  • NIPD Genetics Public Company Ltd.
  • Novartis Oncology
  • ONCOassist
  • OncoDNA
  • Oncology Central
  • Oncology Learning Network
  • OncoRadiomics, s.a.
  • OSE Immunotherapeutics
  • Pfizer Oncology
  • PharmaMar
  • Philips Molecular Pathway Diagnostics
  • PierianDx
  • Pierre Fabre
  • PPD
  • Precision for Medicine, Oncology and Rare Disease
  • Rakuten Medical, Inc.
  • Regeneron Pharmaceuticals, Inc
  • Samsung Bioepis Co., Ltd.
  • Sanofi Genzyme
  • Seattle Genetics
  • Servier
  • Sotio a.s.
  • Springer Healthcare
  • Stemline Therapeutics
  • Syndax Pharmaceuticals
  • Syneos Health
  • Sysmex Inostics GmbH
  • Taiho Oncology, Inc.
  • Takeda Oncology
  • Taylor & Francis
  • Tempus
  • Thermo Fisher Scientific
  • Translational Research in Oncology (TRIO)
  • Unicancer
  • Varian
  • VJOncology
  • WeHealth Digital Medicine
  • Wisepress Ltd.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings